JP7115746B2 - 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用 - Google Patents

掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用 Download PDF

Info

Publication number
JP7115746B2
JP7115746B2 JP2018539149A JP2018539149A JP7115746B2 JP 7115746 B2 JP7115746 B2 JP 7115746B2 JP 2018539149 A JP2018539149 A JP 2018539149A JP 2018539149 A JP2018539149 A JP 2018539149A JP 7115746 B2 JP7115746 B2 JP 7115746B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
mice
pruritus
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507736A (ja
JP2019507736A5 (https=
Inventor
ツァイルホーファー，ハンス・ウルリヒ
ラルヴェニウス，ウィリアム
Original Assignee
ウニヴェルズィテート・ツューリヒ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルズィテート・ツューリヒ filed Critical ウニヴェルズィテート・ツューリヒ
Publication of JP2019507736A publication Critical patent/JP2019507736A/ja
Publication of JP2019507736A5 publication Critical patent/JP2019507736A5/ja
Priority to JP2022062494A priority Critical patent/JP2022088620A/ja
Application granted granted Critical
Publication of JP7115746B2 publication Critical patent/JP7115746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018539149A 2016-01-27 2017-01-27 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用 Active JP7115746B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022062494A JP2022088620A (ja) 2016-01-27 2022-04-04 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16153035.7 2016-01-27
EP16178824.5 2016-07-11
EP16178824 2016-07-11
PCT/EP2017/051866 WO2017129801A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022062494A Division JP2022088620A (ja) 2016-01-27 2022-04-04 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用

Publications (3)

Publication Number Publication Date
JP2019507736A JP2019507736A (ja) 2019-03-22
JP2019507736A5 JP2019507736A5 (https=) 2020-03-05
JP7115746B2 true JP7115746B2 (ja) 2022-08-09

Family

ID=57890845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539149A Active JP7115746B2 (ja) 2016-01-27 2017-01-27 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用
JP2022062494A Pending JP2022088620A (ja) 2016-01-27 2022-04-04 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022062494A Pending JP2022088620A (ja) 2016-01-27 2022-04-04 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用

Country Status (14)

Country Link
US (3) US10786513B2 (https=)
EP (1) EP3407886A1 (https=)
JP (2) JP7115746B2 (https=)
KR (1) KR102482200B1 (https=)
CN (1) CN108697694B (https=)
AU (1) AU2017213154B2 (https=)
BR (1) BR112018015386A2 (https=)
CA (2) CA3012791C (https=)
CL (1) CL2018002023A1 (https=)
IL (1) IL260775B (https=)
MX (1) MX388862B (https=)
SG (1) SG11201806393QA (https=)
UA (1) UA125463C2 (https=)
WO (1) WO2017129801A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017129801A1 (en) 2016-01-27 2017-08-03 Universität Zürich Use of gabaa receptor modulators for treatment of itch
BR112020021104A2 (pt) * 2018-04-18 2021-02-23 Neurocycle Therapeutics, Inc compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos
WO2019226820A1 (en) 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
BR112021004661A2 (pt) * 2018-09-13 2021-06-01 Saniona A/S composto, composição farmacêutica, método para tratamento de dor neuropática e/ou prurido, e, uso do composto
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
CN120267677A (zh) * 2019-10-23 2025-07-08 纽罗塞克医疗公司 用gabaa受体调节剂的癫痫状况的治疗
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514206A (ja) 1997-09-01 2001-09-11 ロレアル 敏感肌の処理における塩素またはカリウムチャネルが付随したレセプターのアゴニストである物質の使用
JP2002514169A (ja) 1996-07-25 2002-05-14 メルク シヤープ エンド ドーム リミテツド Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US20130331394A1 (en) 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
JPWO2005030773A1 (ja) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 新規ピラゾロピリミジン誘導体
US20050245517A1 (en) * 2004-04-29 2005-11-03 Phil Skolnick 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
WO2009021957A2 (en) * 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
TWI472529B (zh) 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
KR20130059400A (ko) 2010-08-25 2013-06-05 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
AU2014219855B2 (en) * 2013-02-19 2017-09-28 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
WO2015072853A1 (en) * 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US10259815B2 (en) 2015-03-20 2019-04-16 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
WO2017129801A1 (en) 2016-01-27 2017-08-03 Universität Zürich Use of gabaa receptor modulators for treatment of itch

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514169A (ja) 1996-07-25 2002-05-14 メルク シヤープ エンド ドーム リミテツド Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体
JP2001514206A (ja) 1997-09-01 2001-09-11 ロレアル 敏感肌の処理における塩素またはカリウムチャネルが付随したレセプターのアゴニストである物質の使用
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US20130331394A1 (en) 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN LONG，JOURNAL OF PAIN，2015年11月11日，VOL:17, NR:2，PAGE(S):181 - 189
DE LUCAS A GARCIA，BIOCHEMICAL PHARMACOLOGY，2014年12月25日，VOL:93, NR:3，PAGE(S):370 - 379
KOHUT S J，PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR，2008年，VOL:90, NR:1，PAGE(S):65 - 73

Also Published As

Publication number Publication date
AU2017213154A1 (en) 2018-08-16
UA125463C2 (uk) 2022-03-16
US12433898B2 (en) 2025-10-07
JP2022088620A (ja) 2022-06-14
EP3407886A1 (en) 2018-12-05
AU2017213154B2 (en) 2023-02-02
CN108697694A (zh) 2018-10-23
US20250268912A1 (en) 2025-08-28
RU2018128905A3 (https=) 2020-03-24
CN108697694B (zh) 2022-12-09
US20210100814A1 (en) 2021-04-08
CA3222584A1 (en) 2017-08-03
US11529359B2 (en) 2022-12-20
CA3012791C (en) 2024-01-23
US10786513B2 (en) 2020-09-29
CL2018002023A1 (es) 2019-02-01
BR112018015386A2 (pt) 2019-03-19
MX2018009252A (es) 2019-01-21
RU2018128905A (ru) 2020-02-27
JP2019507736A (ja) 2019-03-22
WO2017129801A1 (en) 2017-08-03
US20190134057A1 (en) 2019-05-09
IL260775B (en) 2021-09-30
CA3012791A1 (en) 2017-08-03
KR102482200B1 (ko) 2022-12-27
MX388862B (es) 2025-03-20
SG11201806393QA (en) 2018-08-30
KR20180118623A (ko) 2018-10-31

Similar Documents

Publication Publication Date Title
JP7115746B2 (ja) 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用
Calzaferri et al. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases
Dawson et al. An inverse agonist selective for α5 subunit-containing GABAA receptors enhances cognition
Prins et al. 5‐HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle
Saito et al. Neuronal activity‐dependent local activation of dendritic unfolded protein response promotes expression of brain‐derived neurotrophic factor in cell soma
Ralvenius et al. Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
Tsantoulas et al. HCN2 ion channels: basic science opens up possibilities for therapeutic intervention in neuropathic pain
Koster et al. Developmental NMDA receptor dysregulation in the infantile neuronal ceroid lipofuscinosis mouse model
Kurimoto et al. An approach to discovering novel muscarinic M1 receptor positive allosteric modulators with potent cognitive improvement and minimized gastrointestinal dysfunction
US10426815B2 (en) Prevention and treatment of itch with an MRGPR antagonist
Soukup et al. The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors
Li et al. STING controls opioid-induced itch and chronic itch via spinal tank-binding kinase 1-dependent type I interferon response in mice
Li et al. CCR3 and choroidal neovascularization
Kearney et al. Silencing Parkinson’s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability
JP7697879B2 (ja) 筋肉減少症又は廃用性萎縮症の治療のための組成物
CN110121361A (zh) 用于治疗运动神经元疾病的神经节苷脂代谢抑制剂
RU2781636C2 (ru) Применение модуляторов gabaa-рецептора для лечения зуда
Wang et al. Spinal histamine H4 receptor mediates chronic pruritus via p‐ERK in acetone–ether–water (AEW)‐induced dry skin mice
Housley et al. Purinergic signalling: an experimental perspective
HK1262708A1 (en) Use of gabaa receptor modulators for treatment of itch
de Oliveira et al. Ketamine anesthesia helps preserve neuronal viability
EP3386510B1 (fr) Derives phosphores pour la prevention ou le traitement des myopathies et traumatismes musculaires
Wu et al. Spinal TREM2/PI3K/Akt signal axis elicits microglial activation and aggravates bone cancer pain
WO2004039409A2 (de) Zusammensetzung enthaltend aktivatoren von ik-kaliumkanälen und calcineurin-antagonisten und deren verwendung
Yang et al. Rational Design of Dual-Targeting Novel GPE-Derived Oligopeptide Conjugates for Alzheimer’s Disease: Synergistic Inhibition of Excitotoxicity and Oxidative Stress

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220412

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220622

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220721

R150 Certificate of patent or registration of utility model

Ref document number: 7115746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250